Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma.

Kimura O, Kondo Y, Shimosegawa T.

PPAR Res. 2012;2012:574180. doi: 10.1155/2012/574180. Epub 2012 Dec 16.

2.

Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.

de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, Meier CA, Hadengue A, Negro F.

Aliment Pharmacol Ther. 2006 Jan 1;23(1):107-14.

3.
4.
5.

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Baffy G, Brunt EM, Caldwell SH.

J Hepatol. 2012 Jun;56(6):1384-91. doi: 10.1016/j.jhep.2011.10.027. Epub 2012 Feb 9. Review.

7.

Peroxisome proliferator-activated receptors, coactivators, and downstream targets.

Qi C, Zhu Y, Reddy JK.

Cell Biochem Biophys. 2000;32 Spring:187-204. Review.

PMID:
11330046
8.

[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].

Bocher V, Chinetti G, Fruchart JC, Staels B.

J Soc Biol. 2002;196(1):47-52. Review. French.

PMID:
12134632
10.

Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.

Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC.

Clin Cancer Res. 2008 Jul 1;14(13):4045-52. doi: 10.1158/1078-0432.CCR-07-5040.

11.

Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells.

Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P.

Gastroenterology. 2000 Aug;119(2):466-78.

PMID:
10930382
12.

Peroxisome proliferator-activated receptors and the control of inflammation.

Cabrero A, Laguna JC, Vázquez M.

Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):243-8. Review.

PMID:
14561188
13.

A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.

Zhang JY, Dai M, Wang X, Lu WQ, Li DS, Zhang MX, Wang KJ, Dai LP, Han SG, Zhou YF, Zhuang H.

Int J Epidemiol. 1998 Aug;27(4):574-8.

PMID:
9758109
14.
15.

PPAR: a mediator of peroxisome proliferator action.

Green S.

Mutat Res. 1995 Dec;333(1-2):101-9. Review.

PMID:
8538617
16.

[Peroxisome proliferator activated receptors (PPAR) and insulin sensitivity: experimental studies].

Haluzík MM, Haluzík M.

Cesk Fysiol. 2006;55(4):163-8. Review. Czech.

PMID:
17685022
17.

Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons.

Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, D'Angelo B, Di Loreto S.

Neuroscience. 2005;130(2):325-37.

PMID:
15664689
18.

Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.

Touyz RM, Schiffrin EL.

Vascul Pharmacol. 2006 Jul;45(1):19-28. Epub 2006 Jun 16. Review.

PMID:
16782410
19.

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.

Chinetti G, Fruchart JC, Staels B.

Z Kardiol. 2001;90 Suppl 3:125-32. Review.

PMID:
11374025
20.

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.

Starley BQ, Calcagno CJ, Harrison SA.

Hepatology. 2010 May;51(5):1820-32. doi: 10.1002/hep.23594. Review.

PMID:
20432259

Supplemental Content

Support Center